Nomic Bio (formerly nplex biosciences), a Montreal, Canada-based protein profiling company, raised $17M in Series A funding.
The round, which brought total funding raised to date to over US$21m, was led by Lux Capital, joined by SR One and Casdin Capital, with participation from prior institutional investors.
The company intends to use the funds to:
- grow the teams in Montreal and Boston,
- expand access to the platform by increasing profiling capacity to 100,000 samples a quarter by Q2 2022,
- scale the nELISA to 500 on-boarded proteins, and
- begin the development of various new modalities such as the identification of post-translational modification.
Led by Milad Dagher, Ph.D. and CEO, Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. Nomic plans to develop and commercialize a throughput proteomic platform to make the human proteome as broadly and easily accessible as the human genome. It is building the nELISATM, a scalable next-generation platform that leverages advances in DNA nanotechnology, spectral multiplexing, and automation. To date, the company has worked with select partners across the pharmaceutical and biotech industry to advance drug discovery, ranging from mid-sized biotechs to top-ten pharma.
Nomic has labs and offices in Boston.
FinSMEs
09/12/2021